The Latest News from Our Field

We curate a digest of the latest news in our field for advocates, policymakers, community coalitions and all who work toward shaping policies and practices to effectively prevent substance use and treat addiction. Sign up here to receive weekly updates straight to your inbox.

SAMHSA released the results of the 2025 National Survey on Drug Use and Health, an annual national survey that measures the prevalence of substance use, substance use disorder, treatment receipt, recovery, and other measures.
Often in violation of state law, THC beverages line the refrigerated sections of grocery stores and delis, often next to other beverages and in colorful cans.
With control of opioid settlement funds split among various entities in each state, it is often unclear who should take action on questionable expenditures.
The House Energy and Commerce Committee advanced 8 bills aimed at preventing overdoses and curbing the illicit drug supply.
View our curated digest of the latest research news, including a study that reveals a troubling gap in adolescents’ understanding of fentanyl’s potentially lethal risks. Fewer than half of eighth-grade students surveyed considered experimenting with fentanyl once or twice to pose a great risk, while one-third did not regard even regular use as highly dangerous. Although perceived risk increased among older students, substantial racial and ethnic differences remained, with Hispanic eighth graders and Black tenth- and twelfth-grade students generally reporting the lowest levels of perceived risk. These findings demonstrate the need for clear, age-appropriate, and culturally responsive prevention-based education beginning before high school.
A former FDA scientist accused the agency of authorizing Zyn nicotine pouches without knowing what the pouches themselves are made of.
A coalition of public health organizations, pediatricians, and parents filed a federal lawsuit challenging FDA’s new enforcement policy allowing e-cigarettes and nicotine pouches to be marketed without FDA authorization.
Several HHS agencies and the VA are taking steps to advance the development of psychedelic therapies for mental illness, following President Trump's executive order earlier this year.
President Trump nominated Timothy Westlake, an emergency medicine physician and SAMHSA chief of staff, to lead SAMHSA. Dr. Erica Schwartz, Trump's nominee to lead CDC, had a confirmation hearing.
STAT published articles in its “The Deadliest Drug” series on excessive alcohol use outlining recommendations for addressing the alcohol epidemic in the U.S. and highlighting charts that explain the crisis.
Unlike nationally, overdose deaths are rising in Arizona, driven by shifts in the drug supply, widespread use of methamphetamine, high temperatures, and homelessness in the region.
View our curated digest of the latest research news, including a major systematic review and meta-analysis that offers reassuring evidence that requiring cigarettes to contain substantially less nicotine is unlikely to cause widespread compensatory smoking. Across 17 randomized trials involving 5,500 participants, people assigned to very-low-nicotine cigarettes generally did not smoke more cigarettes or experience greater carbon-monoxide exposure than those using conventional cigarettes. By addressing one of the principal concerns surrounding the FDA’s proposed low-nicotine product standard, the findings strengthen the case that such a policy could reduce nicotine dependence without inadvertently increasing exposure to the toxic products of combustion.
The administration has taken several steps to unravel federal antismoking initiatives and delivered significant policy wins to tobacco companies.
DEA issued a proposed rule to place tianeptine, "gas station heroin," in Schedule I of the Controlled Substances Act.
An American Society of Addiction Medicine report on state legislative efforts related to addiction in the first half of 2026 found top priorities included naloxone, insurance coverage, and access to MOUD.
View our curated digest of the latest research news, including a study that found that flavored nicotine-pouch use was nearly universal among U.S. adolescents who had ever tried the products. Among these young people, 97% most often used a non-tobacco flavor, with mint the leading choice, while approximately 80% named ZYN as their most frequently used brand. The findings suggest that flavors and brand appeal may play an important role in adolescent experimentation and support consideration of stronger regulatory protections.
DEA filed its intent to temporarily place certain levels of 7-OH and three related substances into Schedule I of the Controlled Substances Act.
FDA issued orders to allow ZYN nicotine pouches to be marketed as less harmful to health than cigarettes.
CDC required health programs at the state, territorial, tribal, and local level to agree to a list of agency priorities, which deprioritizes harm reduction.
STAT investigations found that the federal government has downplayed alcohol’s risks and derailed efforts to understand and prevent related harms, while the alcohol industry has used allies and money to push favorable policy.
View our curated digest of the latest research news, including how a national study of 1,501 opioid treatment programs (OTPs) found that state methadone policies shape not only access to OTPs, but also the range of services available within them. Programs in states with more restrictive OTP rules were less likely to offer naltrexone and less likely to provide all three FDA-approved medications for opioid use disorder. These programs were also less likely to offer key behavioral health supports, including mental health services, trauma-informed counseling, and contingency management. The findings suggest that restrictive state policies may weaken access to comprehensive, evidence-based OUD care at points of critical treatment entry.
A DOJ memo goes against decades of law and practice that has prioritized community-based care over institutionalization for people with disabilities, mental illness, and substance use disorder.
The AP reported that in an attempt to pursue bigger criminal cases against fentanyl traffickers, DEA agents monitored, but did not seize, shipments of fentanyl pills, allowing many to enter New Mexico communities.
Federal health agencies issued advisories to states on policies to expand access to MOUD, including authorizing pharmacists to prescribe the medications.
The kratom industry has strongly lobbied the administration to resist regulation, working to differentiate kratom from 7-OH products and downplaying the risks associated with kratom.
1 2 3 61